NASDAQ · BOLT
Healthcare · Biotechnology
$3.65
Up+$0.46 (+12.60%)
Updated Oct 10, 2026, 12:58 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BOLT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
BOLT closed at $3.65 after 20 trading sessions, down 7.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $3.545 | $3.65 | $3.4474 | $3.65 | 10.48K |
| Oct 7, 2026 | $3.65 | $3.79 | $3.381 | $3.60 | 54K |
| Oct 6, 2026 | $3.4529 | $3.639 | $3.4529 | $3.51 | 23.26K |
| Oct 5, 2026 | $3.7084 | $3.7084 | $3.3801 | $3.499 | 9.78K |
| Oct 2, 2026 | $3.495 | $3.495 | $3.45 | $3.45 | 885.87 |
| Oct 1, 2026 | $3.61 | $3.615 | $3.48 | $3.51 | 21.67K |
| Sep 30, 2026 | $3.65 | $3.78 | $3.5971 | $3.68 | 9.31K |
| Sep 29, 2026 | $3.46 | $3.65 | $3.46 | $3.60 | 9.55K |
| Sep 28, 2026 | $3.64 | $3.78 | $3.4601 | $3.4601 | 19.97K |
| Sep 25, 2026 | $3.60 | $3.68 | $3.58 | $3.58 | 4.1K |
| Sep 24, 2026 | $3.57 | $3.71 | $3.4646 | $3.59 | 15.28K |
| Sep 23, 2026 | $3.90 | $3.90 | $3.57 | $3.65 | 5.11K |
| Sep 22, 2026 | $3.655 | $3.7999 | $3.45 | $3.71 | 17.85K |
| Sep 21, 2026 | $3.465 | $3.64 | $3.38 | $3.59 | 22.45K |
| Sep 18, 2026 | $3.32 | $3.62 | $3.10 | $3.56 | 249.41K |
| Sep 17, 2026 | $3.67 | $3.67 | $3.20 | $3.345 | 90.47K |
| Sep 16, 2026 | $3.92 | $4.2328 | $3.61 | $3.63 | 29K |
| Sep 15, 2026 | $3.98 | $4.36 | $3.86 | $4.03 | 45.83K |
| Sep 14, 2026 | $3.835 | $4.09 | $3.70 | $3.98 | 19.63K |
| Sep 11, 2026 | $3.72 | $3.955 | $3.57 | $3.95 | 77.08K |
The latest Smart Investors Daily articles mentioning BOLT.
Company
Market Activity
Research & News
BOLT research
Company profile and research snapshot.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 29, 2026 | Rodman & Renshaw | Buy | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | Lake Street | Buy | — |
| May 20, 2025 | Lake Street | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share
Finnhub · Apr 17, 2026
Study Design: Dose Escalation with Cycle 1 Step-Up Dosing Backfill at dose levels cleared for safety Gastric and gastroesophageal cancer patients ...
Benzinga · Mar 13, 2026
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
Benzinga · Mar 12, 2026
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of $(7.60) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BOLT.
